Contributions
Abstract: PB2446
Type: Publication Only
Background
Some new consideration about haplotype of patients with acute leukemia and their binding with genoidentical donors KIR allele in HSCT try to explain few aspects in postHSCT evolution,.
Aims
Some new consideration about haplotype of patients with acute leukemia and their binding with genoidentical donors KIR allele in HSCT try to explain few aspects in postHSCT evolution,.
Methods
Patients with acute leukemia,lymphoblastic and non-lymphoblastic,aplastic anemia and their genoidentical donors are evaluated(eighteen paars). Haplotype HLA sistematisation follow IPD/ KIR : HLA- A3/A11, HLA-Bw4, HLA-Bw6( Bw4 negative) HLA-C1/C1 homozygot, HLA-C1/C2 heterozygot, HLA-C2/C2 homozygot.
Ligand | Activatory allele | Inhibitory allele |
HLA A3/A11 | KIR3DL2 | KIR2DS4 |
HLA Bw4 | KIR3DL1 | KIR3DS1 |
HLA C1 | KIR2DL2, KIR2DL3 | KIR2DS4 |
HLA C2 | KIR2DL1 | KIR2DS1 |
The source of HSCT was PBSC.The method used was PCR-SSP (Innotrain DIAGNOSTIK GMBH,Dynal BIOTECH PEL-FREEZE )The complications like graft versus host disease acute and chronic,relapse,TMA and the recovery with leucocytes and thrombocytes are followed.
Results
HLA-Bw6 haplotype(7) with 85,71% overall survival,HLA-A3/A11(15) with 53,33%,HLA-C2/Cx(17) with 50.00% and presence of all these haplotype at same patient(6) with 83,33% overall survival demonstrate the protective effect and cumulative effect of some categories of HLA haplotype.Donors KIR haplotype are AB , protective ,evident effect at patients with KIR haplotype AA(4:2 AML,1ALL,1AA) but also with favorable HLA.Patients with HLA-Bw6,HLA-C2/C2,HLA-A3/A11(6) don’t develop aGVHD , relapse,TMA,a single patient with HLA-Bw4 develop aGVHD;positive effect also about leucocyte and trombocyte recovery,especially in the presence of actiatory allele(sig,0,5%).HLA-Bw6 haplotype(Bw4 negative) with donor inhibitory KIR3DL1 , confirm ¢¢missing ligand¢ theory¢, (83% OS,sig<0,05);with donor activatory KIR3DS1,OS is 100%(sig<0,05).
Conclusion
Cumulative effect of some patient HLA haplotype with donor KIR haplotype (also patient KIR haplotype )improve overall survival and protect again most complication after HSCT.
Session topic: 23. Stem cell transplantation - Clinical
Keyword(s): KIR, acute leukemia, Hematopoietic cell transplantation, HLA
Abstract: PB2446
Type: Publication Only
Background
Some new consideration about haplotype of patients with acute leukemia and their binding with genoidentical donors KIR allele in HSCT try to explain few aspects in postHSCT evolution,.
Aims
Some new consideration about haplotype of patients with acute leukemia and their binding with genoidentical donors KIR allele in HSCT try to explain few aspects in postHSCT evolution,.
Methods
Patients with acute leukemia,lymphoblastic and non-lymphoblastic,aplastic anemia and their genoidentical donors are evaluated(eighteen paars). Haplotype HLA sistematisation follow IPD/ KIR : HLA- A3/A11, HLA-Bw4, HLA-Bw6( Bw4 negative) HLA-C1/C1 homozygot, HLA-C1/C2 heterozygot, HLA-C2/C2 homozygot.
Ligand | Activatory allele | Inhibitory allele |
HLA A3/A11 | KIR3DL2 | KIR2DS4 |
HLA Bw4 | KIR3DL1 | KIR3DS1 |
HLA C1 | KIR2DL2, KIR2DL3 | KIR2DS4 |
HLA C2 | KIR2DL1 | KIR2DS1 |
The source of HSCT was PBSC.The method used was PCR-SSP (Innotrain DIAGNOSTIK GMBH,Dynal BIOTECH PEL-FREEZE )The complications like graft versus host disease acute and chronic,relapse,TMA and the recovery with leucocytes and thrombocytes are followed.
Results
HLA-Bw6 haplotype(7) with 85,71% overall survival,HLA-A3/A11(15) with 53,33%,HLA-C2/Cx(17) with 50.00% and presence of all these haplotype at same patient(6) with 83,33% overall survival demonstrate the protective effect and cumulative effect of some categories of HLA haplotype.Donors KIR haplotype are AB , protective ,evident effect at patients with KIR haplotype AA(4:2 AML,1ALL,1AA) but also with favorable HLA.Patients with HLA-Bw6,HLA-C2/C2,HLA-A3/A11(6) don’t develop aGVHD , relapse,TMA,a single patient with HLA-Bw4 develop aGVHD;positive effect also about leucocyte and trombocyte recovery,especially in the presence of actiatory allele(sig,0,5%).HLA-Bw6 haplotype(Bw4 negative) with donor inhibitory KIR3DL1 , confirm ¢¢missing ligand¢ theory¢, (83% OS,sig<0,05);with donor activatory KIR3DS1,OS is 100%(sig<0,05).
Conclusion
Cumulative effect of some patient HLA haplotype with donor KIR haplotype (also patient KIR haplotype )improve overall survival and protect again most complication after HSCT.
Session topic: 23. Stem cell transplantation - Clinical
Keyword(s): KIR, acute leukemia, Hematopoietic cell transplantation, HLA